117 related articles for article (PubMed ID: 26249841)
1. Early liraglutide treatment improves β-cell function in patients with type 2 diabetes: a retrospective cohort study.
Kondo Y; Satoh S; Osada UN; Terauchi Y
Endocr J; 2015; 62(11):971-80. PubMed ID: 26249841
[TBL] [Abstract][Full Text] [Related]
2. Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats.
Schwasinger-Schmidt T; Robbins DC; Williams SJ; Novikova L; Stehno-Bittel L
Pharmacol Res; 2013 Oct; 76():58-66. PubMed ID: 23891763
[TBL] [Abstract][Full Text] [Related]
3. Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes patients: The association between remaining β-cell function and the achievement of the glycated hemoglobin target 1 year after initiation.
Usui R; Sakuramachi Y; Seino Y; Murotani K; Kuwata H; Tatsuoka H; Hamamoto Y; Kurose T; Seino Y; Yabe D
J Diabetes Investig; 2018 Jul; 9(4):822-830. PubMed ID: 29106046
[TBL] [Abstract][Full Text] [Related]
4. Comparative Study of Liraglutide and Insulin Glargine on Glycemic Control and Pancreatic β-Cell Function in db/db Mice.
Li Y; Zheng J; Shen Y; Li W; Liu M; Wang J; Zhu S; Wu M
Med Sci Monit; 2018 May; 24():3293-3300. PubMed ID: 29777582
[TBL] [Abstract][Full Text] [Related]
5. The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial.
Kramer CK; Zinman B; Choi H; Connelly PW; Retnakaran R
J Clin Endocrinol Metab; 2015 Oct; 100(10):3702-9. PubMed ID: 26230296
[TBL] [Abstract][Full Text] [Related]
6. Clinical effects of liraglutide are possibly influenced by hypertriglyceridemia and remaining pancreatic β-cell function in subjects with type 2 diabetes mellitus.
Tanabe A; Kaneto H; Kamei S; Hirukawa H; Shimoda M; Kimura T; Obata A; Okauchi S; Tatsumi F; Kohara K; Mune T; Kaku K
J Diabetes Complications; 2016 Aug; 30(6):1201-3. PubMed ID: 27220544
[TBL] [Abstract][Full Text] [Related]
7. A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2).
Nomoto H; Miyoshi H; Furumoto T; Oba K; Tsutsui H; Miyoshi A; Kondo T; Tsuchida K; Atsumi T; Manda N; Kurihara Y; Aoki S;
PLoS One; 2015; 10(8):e0135854. PubMed ID: 26284918
[TBL] [Abstract][Full Text] [Related]
8. Liraglutide improves pancreatic Beta cell mass and function in alloxan-induced diabetic mice.
Tamura K; Minami K; Kudo M; Iemoto K; Takahashi H; Seino S
PLoS One; 2015; 10(5):e0126003. PubMed ID: 25938469
[TBL] [Abstract][Full Text] [Related]
9. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function.
Kielgast U; Krarup T; Holst JJ; Madsbad S
Diabetes Care; 2011 Jul; 34(7):1463-8. PubMed ID: 21593296
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin.
Vanderheiden A; Harrison LB; Warshauer JT; Adams-Huet B; Li X; Yuan Q; Hulsey K; Dimitrov I; Yokoo T; Jaster AW; Pinho DF; Pedrosa I; Lenkinski RE; Pop LM; Lingvay I
J Clin Endocrinol Metab; 2016 Apr; 101(4):1798-806. PubMed ID: 26909799
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes.
Muscelli E; Casolaro A; Gastaldelli A; Mari A; Seghieri G; Astiarraga B; Chen Y; Alba M; Holst J; Ferrannini E
J Clin Endocrinol Metab; 2012 Aug; 97(8):2818-26. PubMed ID: 22685234
[TBL] [Abstract][Full Text] [Related]
12. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
Montanya E; Sesti G
Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
[TBL] [Abstract][Full Text] [Related]
13. Early liraglutide treatment is better in glucose control, β-cell function improvement and mass preservation in db/db mice.
Shao Y; Yuan G; Feng Y; Zhang J; Guo X
Peptides; 2014 Feb; 52():134-42. PubMed ID: 24406898
[TBL] [Abstract][Full Text] [Related]
14. Postprandial metabolic responses to mixed versus liquid meal tests in healthy men and men with type 2 diabetes.
Brodovicz KG; Girman CJ; Simonis-Bik AM; Rijkelijkhuizen JM; Zelis M; Bunck MC; Mari A; Nijpels G; Eekhoff EM; Dekker JM
Diabetes Res Clin Pract; 2011 Dec; 94(3):449-55. PubMed ID: 21955958
[TBL] [Abstract][Full Text] [Related]
15. Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment.
von Scholten BJ; Lajer M; Goetze JP; Persson F; Rossing P
Diabet Med; 2015 Mar; 32(3):343-52. PubMed ID: 25251901
[TBL] [Abstract][Full Text] [Related]
16. Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients.
Fadini GP; Simioni N; Frison V; Dal Pos M; Bettio M; Rocchini P; Avogaro A
Acta Diabetol; 2013 Dec; 50(6):943-9. PubMed ID: 23754673
[TBL] [Abstract][Full Text] [Related]
17. Early intervention with glucagon-like peptide 1 analog liraglutide prevents tau hyperphosphorylation in diabetic db/db mice.
Ma DL; Chen FQ; Xu WJ; Yue WZ; Yuan G; Yang Y
J Neurochem; 2015 Oct; 135(2):301-8. PubMed ID: 26183127
[TBL] [Abstract][Full Text] [Related]
18. The effect of liraglutide on endothelial function in patients with type 2 diabetes.
Nandy D; Johnson C; Basu R; Joyner M; Brett J; Svendsen CB; Basu A
Diab Vasc Dis Res; 2014 Nov; 11(6):419-30. PubMed ID: 25212693
[TBL] [Abstract][Full Text] [Related]
19. The duration of sulfonylurea treatment is associated with β-cell dysfunction in patients with type 2 diabetes mellitus.
Shin MS; Yu JH; Jung CH; Hwang JY; Lee WJ; Kim MS; Park JY
Diabetes Technol Ther; 2012 Nov; 14(11):1033-42. PubMed ID: 22958196
[TBL] [Abstract][Full Text] [Related]
20. The beneficial effect of metformin on β-cell function in non-obese Chinese subjects with newly diagnosed type 2 diabetes.
Bi Y; Tong GY; Yang HJ; Cai MY; Ma JH; Liang J; Xin B; Miao H; Peng ZH; Zhu DL
Diabetes Metab Res Rev; 2013 Nov; 29(8):664-72. PubMed ID: 23955995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
